Mifepristone 300 MG [Korlym] + Placebo for mifepristone
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypercortisolism
Conditions
Hypercortisolism, Diabetes Mellitus, Type 2
Trial Timeline
Mar 31, 2023 → Dec 18, 2024
NCT ID
NCT05772169About Mifepristone 300 MG [Korlym] + Placebo for mifepristone
Mifepristone 300 MG [Korlym] + Placebo for mifepristone is a approved stage product being developed by Corcept Therapeutics for Hypercortisolism. The current trial status is completed. This product is registered under clinical trial identifier NCT05772169. Target conditions include Hypercortisolism, Diabetes Mellitus, Type 2.
What happened to similar drugs?
0 of 1 similar drugs in Hypercortisolism were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05772169 | Approved | Completed |
Competing Products
1 competing product in Hypercortisolism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Relacorilant | Corcept Therapeutics | Phase 3 | 37 |